Phase I study of TAC‐101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma

Preclinical models have shown that TAC‐101 (4‐[3,5‐bis(trimethylsilyl) benzamide] benzoic acid), an oral synthetic retinoid, has antitumor activity in hepatocellular carcinoma (HCC). We conducted a phase I study in Japanese patients with advanced HCC to examine the pharmacokinetics, recommended dose...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Autores principales: Okusaka, Takuji, Ueno, Hideki, Ikeda, Masafumi, Takezako, Yoriko, Morizane, Chigusa
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2012
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7659330/
https://ncbi.nlm.nih.gov/pubmed/22587457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02334.x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares